Okay, thank you, Mark. Beginning with revenue, our total revenue from continuing operations for the fourth quarter was $13.4 million compared to last year's fourth quarter of $15.1 million, a decrease of $1.7 million or 11.3%. The treatment segment was relatively consistent to prior year with revenue only modest down by $193,000 or 2% but our services segment was down $1.5 million or 26.8%. While our treatment shipments did show improvement from the earlier part of the year, the drop in services revenue was a result of the completion of a significant contract that concluded in the fourth quarter. For the year ended 2016 our revenue was $51.2 million, well below $62.4 million in 2015. We experienced delays in the first three quarters of 2016 primarily related to the shipments from our government customers in the treatment segment and that accounted for approximately 81% of our shortfall. On the cost of goods sold, our total cost of sales was $10 million in the fourth quarter compared to $11.2 million in the prior year, a reduction of $1.2 million or 10.7%. Our treatment segment cost of sales decreased $283,000, primarily from the lower variable cost related to lower revenue but offset by an increase in our facility cost -- fixed facility cost which were brought about by our decision to close our MNEC location as we accelerated certain depreciation of certain assets. Our cost of sales from the services segment were down $916,000 with variable expenses related to lower revenue accounting for $886,000 and the remainder of about $30,000 from lower expenses. Our gross profit was $3.4 million compared to $3.5 million -- $3.9 million in 2015. The shortfall of $468,000 was primarily volume related but was offset by an improved revenue mix. For the year ended 2016, gross profit is $7.1 million compared to $14.4 million in 2015; again the lower revenue resulting from the shipment delays in the treatment segment is the primary reason for the gross profit shortfall. Our total SG&A cost for the quarter were $2.6 million compared to $2.3 million last year, an increase of approximately $228,000. Higher legal expenses and the large bad debt recovery in 2015 was the main reason for this variance. Our income from continuing operations for the quarter before taxes was $317,000 compared to income of $677,000 last year. Our net income attributable to common shareholders for the quarter was $226,000 compared to last year's net income of $97,000. Our year-to-date losses from both continuing operations and attributable to common shareholders included impairment charges write-offs and a tax benefit related to the closure of our MNEC location which totaled approximately $7.5 million. Our total income per share for the quarter was $0.02 per share compared to income per share of $0.01 in prior year. Our adjusted EBITDA from continuing operations for the quarter is defined in this morning's press release was $1.9 million compared to $2.5 million last year. Looking forward at some balance sheet items compared to 2015 year end, our cash was down $1.4 million which was representative of the spending in our Perma-Fix medical subsidiary which we consolidate. Our accounts receivable and unbilled receivable collectively were down approximately $2.6 million due to improved collections and lower revenue in 2016. Our other current assets were down $1.6 million due to a write-off of $587,000 at MNEC and a reduction of various other prepaid and receivables. Our intangibles and other assets were down $9 million which was a result of our write-off of the permit at MNEC. Our waste backlog finished at $5.2 million which was up from $4.7 million in 2015. Our long-term liabilities were down $2.9 million as a result of reclassifying the majority of our closure liability at MNEC from long-term to current. Our current debt was $1.2 million which was down $1.3 million of 2015 reflecting the pay-off of the shareholder loan in August 2016, and our total debt excluding debt issuances costs at quarter end was $9 million and this is all due to our lender P&C Bank. I'll next summarize our cash flow; our cash provided by continuing operations was $1.1 million, and I do want to note that that -- because of the consolidation of our medical that does include $1.4 million of spending by our medical group. So our core operations actually generated more of that. Cash from discontinued ops -- used by discontinued ops was $959,000. Our cash used for investing in continuing operations was $499,000 of which $436,000 was for cap spending. Our cash provided by investing activities of discontinued operations was $84,000 and cash used for financing was $956,000. Finally I'm going to address our working capital. Our working capital at year end was at a deficit of $2.1 million and again this was the result of reclassifying most of our closure liability of $2.2 million at MNEC as current due to the projected closure date of January 2018. As Lou mentioned earlier, we've also initiated a change in our bonding mechanism at Perma-Fix Northwest facility which will enable us to free-up approximately $3.5 million from our fine out risk thinking fund as we await sign-off from one of the regulators we continue to classify these funds as long-term. With that operator, I'll now open the call for questions.